{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T14:24:21Z","timestamp":1754144661250,"version":"3.41.2"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reports"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.pharep.2019.02.001","type":"journal-article","created":{"date-parts":[[2019,2,10]],"date-time":"2019-02-10T09:52:37Z","timestamp":1549792357000},"page":"473-477","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pixantrone, etoposide, bendamustine, rituximab (P[R]EBEN) as an effective salvage regimen for relapsed\/refractory aggressive non-Hodgkin lymphoma\u2014Polish Lymphoma Research Group real-life analysis"],"prefix":"10.1007","volume":"71","author":[{"given":"Monika","family":"D\u0142ugosz-Danecka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iwona","family":"Hus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bartosz","family":"Pu\u0142a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Artur","family":"Jurczyszyn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomasz","family":"Chojnacki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beata","family":"Blajer-Olszewska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna","family":"Drozd-Soko\u0142owska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ma\u0142gorzata","family":"Ra\u017any","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna","family":"Romejko-Jarosi\u0144ska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Micha\u0142","family":"Taszner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wojciech","family":"Jurczak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"issue":"4","key":"10.1016\/j.pharep.2019.02.001_bib0005","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.pharep.2019.02.001_bib0010","doi-asserted-by":"crossref","first-page":"5027","DOI":"10.1200\/JCO.2005.09.137","article-title":"Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia","volume":"23","author":"Sehn","year":"2005","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.pharep.2019.02.001_bib0015","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.pharep.2019.02.001_bib0020","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin\u2019s lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.pharep.2019.02.001_bib0025","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1200\/JCO.2007.15.7479","article-title":"Hematopoietic cell transplantation for non-Hodgkin\u2019s lymphoma: yesterday, today, and tomorrow","volume":"26","author":"Appelbaum","year":"2008","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.pharep.2019.02.001_bib0030","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1200\/JCO.1999.17.12.3776","article-title":"Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin\u2019s lymphoma","volume":"17","author":"Moskowitz","year":"1999","journal-title":"J Clin Oncol"},{"issue":"27","key":"10.1016\/j.pharep.2019.02.001_bib0035","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.pharep.2019.02.001_bib0040","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1200\/JCO.2012.46.0188","article-title":"Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma","volume":"31","author":"Smith","year":"2013","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.pharep.2019.02.001_bib0045","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1200\/JCO.2005.09.131","article-title":"Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte","volume":"23","author":"Feugier","year":"2005","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.pharep.2019.02.001_bib0050","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/bmt.2015.213","article-title":"Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study","volume":"51","author":"Van Den Neste","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"13","key":"10.1016\/j.pharep.2019.02.001_bib0055","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.2174\/092986709788186228","article-title":"New developments in anthracycline-induced cardiotoxicity","volume":"16","author":"Mordente","year":"2009","journal-title":"Curr Med Chem"},{"issue":"4","key":"10.1016\/j.pharep.2019.02.001_bib0060","doi-asserted-by":"crossref","first-page":"427","DOI":"10.18388\/abp.1995_4896","article-title":"Aza and diaza bioisosteric anthracene-9,10-diones as antitumor agents","volume":"42","author":"Krapcho","year":"1995","journal-title":"Acta Biochim Pol"},{"issue":"13","key":"10.1016\/j.pharep.2019.02.001_bib0065","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1056\/NEJM199809243391307","article-title":"Doxorubicin-induced cardiomyopathy","volume":"339","author":"Singal","year":"1998","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.pharep.2019.02.001_bib0070","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/cncr.11407","article-title":"Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials","volume":"97","author":"Swain","year":"2003","journal-title":"Cancer"},{"issue":"1\u20132","key":"10.1016\/j.pharep.2019.02.001_bib0075","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1080\/15216540252774829","article-title":"Human heart cytosolic reductases and anthracycline cardiotoxicity","volume":"52","author":"Mordente","year":"2001","journal-title":"IUBMB Life"},{"issue":"6","key":"10.1016\/j.pharep.2019.02.001_bib0080","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s40261-018-0635-3","article-title":"Long-term response and remission with pixantrone in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: post-hoc analysis of the multicenter, open-label, randomized PIX301 trial","volume":"38","author":"Pettengell","year":"2018","journal-title":"Clin Drug Investig"},{"issue":"22","key":"10.1016\/j.pharep.2019.02.001_bib0085","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.1782.1782","volume":"128","author":"Clausen","year":"2016","journal-title":"Blood"},{"issue":"S2","key":"10.1016\/j.pharep.2019.02.001_bib0090","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/hon.2440_7","article-title":"A phase 1\/2 study of pixantrone, etoposide, bendamustine and, in CD20+ tumors, rituximab in patients with relapsed aggressive B- or T-cell lymphomas- the P[R]EBEN study","volume":"35","author":"d\u2019Amore","year":"2017","journal-title":"Hematol Oncol"},{"issue":"15","key":"10.1016\/j.pharep.2019.02.001_bib0095","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.2217\/fon-2016-0137","article-title":"Pixantrone-rituximab versus gemcitabine-rituximab in relapsed\/refractory aggressive non-Hodgkin lymphoma","volume":"12","author":"Belada","year":"2016","journal-title":"Future Oncol"},{"issue":"10","key":"10.1016\/j.pharep.2019.02.001_bib0100","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.clml.2018.07.285","article-title":"Phase I study of the combination of bendamustine, rituximab, and pixantrone in patients with relapsed\/refractory B-cell non-Hodgkin lymphoma","volume":"18","author":"Heyman","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"19","key":"10.1016\/j.pharep.2019.02.001_bib0105","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","article-title":"The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications","volume":"117","author":"Campo","year":"2011","journal-title":"Blood"},{"issue":"27","key":"10.1016\/j.pharep.2019.02.001_bib0110","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.pharep.2019.02.001_bib0115","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.2147\/DDDT.S136988","article-title":"Lugano 2014 criteria for assessing FDG-PET\/CT in lymphoma: an operational approach for clinical trials","author":"Van Heertum","year":"2017","journal-title":"Drug Des Devel Ther"},{"issue":"5","key":"10.1016\/j.pharep.2019.02.001_bib0120","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/bjh.15412","article-title":"How I manage patients with relapsed\/refractory diffuse large B cell lymphoma","volume":"182","author":"Gisselbrecht","year":"2018","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.pharep.2019.02.001_bib0125","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/S1470-2045(12)70212-7","article-title":"Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial","volume":"13","author":"Pettengell","year":"2012","journal-title":"Lancet Oncol"},{"issue":"16","key":"10.1016\/j.pharep.2019.02.001_bib0130","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.pharep.2019.02.001_bib0135","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1365-2141.2005.05603.x","article-title":"Conventional second-line salvage chemotherapy regimens are not warranted in patients with malignant lymphomas who have progressive disease after first-line salvage therapy regimens","volume":"130","author":"Ardeshna","year":"2005","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.pharep.2019.02.001_bib0140","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3816\/CLML.2010.n.030","article-title":"Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategies","volume":"10","author":"Elstrom","year":"2010","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"10.1016\/j.pharep.2019.02.001_bib0145","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1159\/000458147","article-title":"Single-agent pixantrone as a bridge to autologous stem cell transplantation in a patient with refractory diffuse large B-cell lymphoma","volume":"62","author":"Appio","year":"2017","journal-title":"Chemotherapy"},{"issue":"4","key":"10.1016\/j.pharep.2019.02.001_bib0150","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1159\/000465511","article-title":"Impressive response to pixantrone after allogeneic transplant in a multiple relapsed diffuse large B-cell lymphoma","volume":"137","author":"Malaspina","year":"2017","journal-title":"Acta Haematol"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1734114018306996?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1734114018306996?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T20:37:54Z","timestamp":1752611874000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1016\/j.pharep.2019.02.001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S1734114018306996"],"URL":"https:\/\/doi.org\/10.1016\/j.pharep.2019.02.001","relation":{},"ISSN":["1734-1140"],"issn-type":[{"type":"print","value":"1734-1140"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pixantrone, etoposide, bendamustine, rituximab (P[R]EBEN) as an effective salvage regimen for relapsed\/refractory aggressive non-Hodgkin lymphoma\u2014Polish Lymphoma Research Group real-life analysis","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharep.2019.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier B.V. on behalf of Institute of Pharmacology, Polish Academy of Sciences.","name":"copyright","label":"Copyright"}]}}